Add-on Acquisition • Medical Products

Bausch Health Acquires Synergetics USA

On October 15, 2015, Bausch Health acquired medical products company Synergetics USA

Acquisition Context

This is Bausch Health’s 6th transaction in the Medical Products sector.
This is Bausch Health’s 20th transaction in the United States.
This is Bausch Health’s 1st transaction in Montana.

Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free

M&A Deal Summary
Date	October 15, 2015
Target	Synergetics USA
Sector	Medical Products
Buyer(s)	Bausch Health
Deal Type	Add-on Acquisition
Advisor(s)	William Blair (Financial) Armstrong Teasdale (Legal)

Target Company

Synergetics USA

O’Fallon, Montana, United States

Synergetics USA, Inc. is a provider fo precision surgical devices.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Bausch Health

Laval, Quebec, Canada

Category	Company
Sector	Life Science
Employees	20,270
Revenue	9.6B USD (2024)

DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.

Deal Context for Buyer	#
Overall	33 of 36
Sector: Medical Products	6 of 6
Type: Add-on Acquisition	25 of 26
State: Montana	1 of 1
Country: United States	20 of 23
Year: 2015	6 of 6

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2015-08-20	Sprout Pharmaceuticals Raleigh, North Carolina, United States Sprout Pharmaceuticals, Inc. is a life science company focused on women's sexual health. Sprout is passionate about women's sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.	Buy	$1.0B

DATE

TARGET

DEAL TYPE

VALUE

2015-08-20

Sprout Pharmaceuticals

Raleigh, North Carolina, United States

Sprout Pharmaceuticals, Inc. is a life science company focused on women's sexual health. Sprout is passionate about women's sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

Buy

$1.0B

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2017-01-09	Dendreon Pharmaceuticals Seattle, Washington, United States Dendreon Pharmaceuticals, Inc. is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.	Sell	$820M

DATE

TARGET

DEAL TYPE

VALUE

2017-01-09

Dendreon Pharmaceuticals

Seattle, Washington, United States

Dendreon Pharmaceuticals, Inc. is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

Sell

$820M

Explore Related M&A Activity

Medical Products M&A - Add-on Acquisition M&A Deals - Montana M&A - United States M&A - 2015 M&A